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Abstract
This review highlights the principal effects of steroid hormones at central and peripheral levels in 
the neuroendocrine axis. The data discussed here points out the principal role of estrogens and 
testosterone in hormonal programming in relation to sexual orientation, reproductive and 
metabolic programming, and in the neuroendocrine mechanism involved in development of 
polycystic ovary syndrome phenotype. Moreover, consistent with the wide range of processes in 
which steroid hormones take part, we discuss the protective effects of progesterone on 
neurodegenerative disease and the signaling mechanism involved in the genesis of estrogen-
induced pituitary prolactinomas.
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 Introduction
Hormones influence many biological processes throughout the lifespan, and have the 
potential to cause permanent tissue-specific alterations in anatomy and physiology during 
important developmental periods. Hormones exert transient effects in adult animals that 
activate or facilitate physiological processes or behaviors while the hormone is present and 
permanent effects that act during development to program the pattern and extent of adult 
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responses and contribute to sex differences. The role of steroid hormones in organizational 
and activational processes participating in reproductive anatomy is well described. These 
processes affect sexual differences of the neuroendocrine system and behavior. Organization 
refers to the actions of hormones in critical periods in early development obtaining 
permanent establishment of sexual phenotypes, sexual genitalia and future potential for 
masculine and feminine mating behavior (1–5). Activation is related to the high levels of 
hormones in puberty or adulthood, linked with changes in masculine and feminine anatomy, 
as well as breeding behavior depending the season of the year (1–5).
The developmental and programming effects of steroid hormones on the brain only occur 
during a sensitive period in early life, commonly referred to as the critical period. This 
period is in close relation with the theory of organizational effects of steroid hormones, is an 
empirical concept that differs among species with regard to timing and brain functions 
involved (6–11). These early effects are permanent and act to hardwire the brain.
Steroid hormones are lipophilic molecules utilized as chemical messengers by organisms, in 
which they act on a wide range of tissues and biological functions (6,12). A number of 
pathological states arise because of problems related to steroid hormone action. These 
include cancer, steroid insensitivity, abnormal fertility, endocrine alterations. Steroid 
hormones derive from a common cholesterol precursor (Cholestane C27). There are four 
major types of steroids: progestins, androgens, estrogens, and corticoids. The rate-limiting 
step in the synthesis of steroid hormones is the transport of free cholesterol (C27) from the 
cytoplasm into mitochondria, which is controlled by Steroidogenic Acute Regulatory Protein 
(STAR). The enzymatic step from cholesterol (C27) to pregnenolone (C21) (the common 
branch point for synthesis of progestins, corticoids, androgens, and therefore estrogens) is 
the limiting step for steroidogenesis once cholesterol is inside the mitochondria. 
Pregnenolone is subsequently converted to progesterone by 3β-hydroxysteroid 
dehydrogenase (3β-HSD). Progesterone is generated in the ovary, the adrenal gland, the 
placenta during pregnancy and the nervous system, in which it plays an important role as a 
neurosteroid. This steroid is the principal intermediate for circulating androgens and 
estrogens. (13–17).
Leydig cells of the testes, thecal cells of the ovary, and cells in the reticularis region of the 
adrenals are responsible for androgen synthesis and secretion (7,11,18). Luteinizing 
hormone (LH) enhances the synthesis in the testes of testosterone (T). T can be reduced by 
5α-reductase to yield subsequently a more active metabolite: 5α-dihydrotestosterone (DHT). 
This process takes part mainly in the target tissues. In some target tissues, T and 
androstenedione can also be transformed into the estrogens, such as 17β-estradiol (E2) and 
estrone by the cytochrome P450 enzyme aromatase (19).
In females, estrogens and progestins are synthesized and secreted principally by maturing 
ovarian follicles, corpora lutea and during pregnancy, the placenta. The dominant estrogen 
secreted is E2. The follicle is composed of the primary oocyte surrounded by granulosa cells 
and theca cells. The granulosa cells are responsible for producing estrogens from androgen 
precursors synthesized from the theca cells; this hormone activates estrogen receptors (ERs) 
in target cells exerting their effects slowly, as a typical steroid receptor. Although most 
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characterized effects are mediated via nuclear receptors and genomic pathways, there are 
many examples of very rapid, nongenomic effects of steroids (20,21). Classical ERs present 
in the cell nucleus (i.e. ERα and ERβ) act as ligand-activated transcriptional regulators, 
whereas ERs present in the cell membrane and cytoplasm regulate various intracellular 
signaling pathways and can converge with nuclear ERs to exert genotropic effects. Putative 
mERs include membrane-associated splice variants of ERα (mERα) and ERβ (mERβ) as 
well as G-protein receptors such as GPR30 and Gq-mER (20,21).
The mechanisms of action for different steroid hormones are relatively similar in the 
different target tissues. In the physiological situation of low amounts of hormone, classical 
ER, androgen (AR), and progesterone (PR) receptors are principally localized in the nucleus 
(22), whereas glucocorticoid receptors (GR) are located in the cytoplasm. Steroid hormones 
move passively from the circulation and interstitial spaces across cell membranes, and bind 
to and activate nuclear steroid receptor proteins. Then the hormone-receptor binds to specific 
short DNA sequences in the promoter region of genes (i.e., hormone response elements) to 
enhance or repress the transcription of genes.
Steroid hormones are implicated in many biological processes including development, 
hypothalamic programming, sexual differentiation, reproductive physiology, behavior, 
osmoregulation, metabolism, regulation of the hypothalamic-pituitary-gonadal axis, and 
hypothalamic-pituitary-adrenal axis (6,16,23–26).
In this review, the programming effect of steroid hormones during prenatal development will 
be discussed. In particular, we will analyze the effects of prenatal steroids on epigenetic 
programming, and their impact in pathologies such as polycystic ovarian disease, and their 
role in behavioral processes like sexual partner preferences. Furthermore, we will discuss the 
protective effects of progesterone in the neurodegenerative disease amyotrophic lateral 
sclerosis (ALS) and consider how the Notch signaling pathway may mediate the formation 
of estrogen-induced prolactinomas.
 I- Steroid Hormones and Programming
 Estrogen
 Developmental and Programming Effects of Steroids During Rat Ovary 
Development—Exposure to high levels of steroidal hormones disrupts normal endocrine 
function and decreases fertility in mammals including humans, especially when the exposure 
occurs during critical periods of vulnerability during development.
The established view holds that reproductive function is regulated through the integration of 
information that comes from the hypothalamus, hypophysis, and ovaries, and that 
gonadotropins modulate folliculogenesis and steroidogenesis in the ovary (27). Numerous 
studies performed to understand the neural circuits and molecular mechanisms that regulate 
GnRH release and steroid feedback demonstrate important roles for classical steroid 
receptors, membrane steroids receptors and neurosteroids in the hypothalamus (28–30).
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Parallel to the endocrine control of reproductive function, experimental evidence indicates 
that there is complementary regulation through the hypothalamus-celiac ganglion-ovary axis 
(31). The primary neurotransmitter acting in the ovary is noradrenaline (NA), which is 
released from neuron terminals originating in the celiac ganglia and acting on the thecal 
layer of ovarian follicles (32).
In mammals, ovarian folliculogenesis starts with the formation of primordial follicles, a 
process known as nest breakdown, which allows the oocytes to be surrounded by a layer of 
somatic cells, thus forming the primordial follicles in a process known as follicular assembly 
(33). In humans, this process occurs during the third trimester of gestation, whereas in rats it 
occurs between 24 and 72 hours after birth (25,34–36). Once follicular development begins, 
it continues throughout postnatal life in both species. During this time the oocyte enlarges 
while the granulosa and theca cells proliferate, increasing the layers of cells surrounding the 
oocyte. This proliferative phase ends as follicular fluid begins to accumulate and the antral 
cavity forms (33,34). Each of the different steps of follicular development is controlled by 
different endocrine and paracrine factors (gonadotropins, growth factors, and steroidal 
hormones); making this process vulnerable to hormonal changes induced by external factors 
(37).
The growing incidence of infertility and reproductive disorders in humans and wildlife has 
alerted many researchers to the influence that products with estrogenic activity that are 
produced and released into the environment have over reproductive function (38). The 
molecules that mimic or block hormonal activity are known as endocrine disruptors (EDs). 
They may be synthetic or natural in origin and can alter homeostasis and the hormonal 
system, either by environmental exposure or by inappropriate exposure during development 
(35). Exposure to EDs during the sensitive periods can alter the normal development of the 
ovary, causing alterations in morphological and follicular development and malfunctions 
during the adult period (39–43). These alterations in the rat ovary can be inherited by the 
next generation through changes in the pattern of DNA methylation, because cellular 
differentiation of the rat ovary begins around the time of birth. The germ cell re-methylation 
is initiated during the postnatal period and continues throughout the oocyte growth period 
until the preantral follicle stage (34,43,44). Regardless of the source of hormones or EDs 
during this period, they would alter the normal development of the offspring due to a 
reprogramming of the genes.
There are several pathological conditions in which the hormonal environment is altered 
during development, such as adrenal hyperplasia, obesity, and polycystic ovary syndrome 
(PCOS) (45,46). PCOS is a complex endocrine disorder characterized by hyperandrogenism, 
ovulatory/menstrual irregularity, and polycystic ovaries, which affects 5–10% of women of 
reproductive age (47). Women with PCOS exhibit a significant increase in androgen 
concentrations during pregnancy (48). An important proportion of the first-degree female 
relatives of women with PCOS have been shown to be at risk for developing PCOS (49). In 
fact, in comparison with control girls, PCOS girls exhibit higher levels of anti-Müllerian 
hormone (AMH), a marker of growing follicles, beginning at the peripubertal stage (50,51). 
It has been proposed that this inheritance is not the result of a genetic condition, but is due to 
fetal programming (47–52). Supporting this, experimental treatment of PCOS gestating 
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mothers with the insulin sensitizer drug metformin improved the altered endocrine-
metabolic environment of the PCOS mothers and the AMH levels in their daughters, 
suggesting the follicular alterations described in adult PCOS women may appear early 
during development (53). This is supported by several studies in animal models that have 
demonstrated a relationship between programmed polycystic ovary (PCO) morphology 
during adulthood and prenatal or neonatal exposure to endocrine-disrupting compounds such 
as estrogens or aromatizable androgens (41,54–56).
The administration of a single dose of estradiol valerate (EV) to neonatal rats (at 12 hours 
postnatal) induces early vaginal opening, disrupted cyclicity, appearance of a PCO 
phenotype, absence of corpus luteum, and infertility (41). In addition, this exposure 
decreases the total number of ovarian follicles mainly due to a reduced number of primordial 
follicles suggesting that estradiol acts in the first stages of folliculogenesis when primordial 
follicles are organizing and reprogramming the genes that control ovarian function (42,57). 
At the molecular level, AMH expression is increased in the ovary of these rats when adults. 
In contrast to AMH expression, AR expression in granulosa cells decreased at the same 
stage of development suggesting that the regulatory region of AR and AMH genes could be 
involved. These results have been confirmed by protein expression data found by 
immunohistochemistry. In summary, these data suggest that estradiol exposure during the 
neonatal critical period reprograms AR and AMH expression in the ovary possibly through 
epigenetic mechanisms that become evident in the adult period, when the full PCO 
phenotype is acquired (57).
 Testosterone
 Prenatal Programming of Sexual Partner Preferences: The Ram Model—
Mammals are exposed to gonadal, placental and maternal hormones during early 
development. Hormones must be maintained within an appropriate range over time to 
program proper development of the reproductive axis and adult behavioral responses (58). 
Males develop in an environment of elevated T secreted by the fetal testes that acts to 
masculinize and defeminize brain structures, physiological processes and behaviors. 
Differences in T concentrations and sensitivity occur naturally between individuals and can 
result from environmental challenges during pregnancy. The question of whether the 
occurrence of same sex partner preferences originates from variations in the prenatal 
hormonal environment has been studied in using a unique ram model (59).
 Domestic Rams Display Variations in Sexual Partner Preferences: Domestic sheep are 
one of the few mammals apart from humans that exhibit exclusive and durable same sex 
partner preferences. Approximately 8–10% of domestic rams exhibit a sexual preference for 
other rams i.e., male-oriented rams (60–63). These rams not only mount, but also direct all 
courtship activities (anal-genital smelling, kicks, nibbles) to other rams, while their sexual 
interest and activity towards females is extremely low or nonexistent. Several hypotheses 
have been proposed to explain the development of same-sex preferences in rams. These 
include effects attributed to same-sex rearing, genes, olfactory responsiveness and brain 
differences (59). Although none of these mechanisms has been extensively investigated, the 
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most compelling evidence supports the idea that this behavior is partially attributable to 
brain differences.
 Medial Preoptic Area: The medial preoptic area is essential for mating behavior in 
vertebrates (64). Thus, this structure has been of great interest in searching for anatomic 
differences that could be causally related to sexual preferences. In rats, there is a cluster of 
neurons in the medial preoptic area, called the sexually dimorphic nucleus of the preoptic 
area (SDN-POA), which is 5 to 7 times larger in males than in females (65). The SDN-POA 
is part of a forebrain circuit that integrates sensory cues with hormonal status to modulate 
sexual behavior. The larger volume of the male SDN-POA is correlated to the higher 
concentration of fetal and neonatal T levels in males than in females. Males castrated at birth 
have much smaller SDN-POAs in adulthood, whereas females treated with T perinatally 
have larger male-like SDN-POAs as adults. Also, there is evidence that conversion of T to 
estradiol by the aromatase enzyme is required to masculinize the SDN-POA (66). Much like 
in rats, sheep have a homologue of the SDN-POA, called the ovine SDN (oSDN) that is 
twice as large in rams than in ewes (62). The oSDN is a dense cluster of cells comprising the 
central component of the medial preoptic nucleus that can be identified by Nissl staining and 
by abundant expression of aromatase mRNA. Moreover, it is larger in female-oriented rams 
than in male-oriented rams and does not differ between male-oriented rams and ewes. The 
differences in volume persist even after adults are gonadectomized and treated with T, 
demonstrating they are most likely the result of the organizational actions of gonadal 
steroids occurring during fetal development in sheep (67).
 Brains Of Straight And Gay Men Differ: The observation that male-oriented rams have 
a smaller oSDN than female-oriented rams is reminiscent of the anatomical difference 
observed between the brains of gay and straight men (68). The sexually dimorphic nucleus 
identified in the hypothalamus of humans is called the 3rd interstitial nucleus of the anterior 
hypothalamus (INAH3). The INAH3 is twice as large in straight men than in gay men and 
women. These cross-species results are some of the strongest evidence that sexual partner 
preferences and sexual orientation are regulated at the level of the hypothalamus-preoptic 
area. But neither study can address the question of whether the difference is the cause or 
consequence of the behavior. In fact, for obvious ethical reasons this question can only be 
experimentally tested using an animal model.
 Which Comes First?: If the smaller size of the oSDN causes males to be attracted to 
other males, the difference in size should be present prior to expression of the behavior. 
Ideally, the volume of the oSDN should be measured over time as the animals become more 
sexually experienced in order to determine whether size differences emerge before sexual 
preferences are expressed. In lieu of this approach, which is not technically feasible, it can 
be asked whether the oSDN develops before animals have social experiences, i.e. prenatally. 
Masculinization of sexual behavior in sheep occurs during a critical period that begins 
shortly after the testes differentiate at gestational day (GD)30 and persists until about GD90 
(term pregnancy in sheep is ~150 days)(69). The oSDN is clearly apparent after this critical 
period in lamb fetuses (GD135) and is twice as large in males as in females (70). The larger 
oSDN in males correlates with higher levels of T during the critical period. Thus, 
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development of the oSDN occurs independently from sexual experiences and prior to 
expression of sexual preferences.
Experiments were performed to directly test whether T exposure determines oSDN volume 
in late gestation fetuses (70). Biweekly maternal treatment with T from GD30 to 90 
significantly enlarged the fetal oSDN in females, but had no effect in males. Coincident with 
this, T-exposed females exhibited masculinized genitalia consisting of a pseudopenis and 
empty scrotum. These results show that in sheep, like rats, T acting during the critical period 
for sexual differentiation masculinizes both the brain and external genitalia. Typically, the 
sex of the brain matches the genitals. But male-oriented rams have male genitals and a 
female-typical oSDN suggesting that separate critical periods for the genitals and the brain 
might exist within the broad period of sexual differentiation. To test this possibility, 
biweekly maternal treatments with T were administered from GD30 to 60 (early T) and 
GD60 to 90 (late T) (71). Early T masculinized the genitalia of genetic females, but had no 
effect on the fetal oSDN. Conversely, late T masculinized the fetal oSDN of females and had 
no effect on the genitalia. Neither maternal treatment significantly affected male fetuses. 
These results demonstrate that T affects differentiation of the brain and genitals in different 
timeframes. Individual critical periods exist for other sexually dimorphic traits in sheep, 
such as urination posture, the LH surge mechanism and the timing of puberty. Distinct 
temporal requirements for T action or different sensitivities to T metabolites could explain 
how hormone variations during gestation can produce rams that prefer to mate with other 
rams but still possess normal masculine genitals and other typical male neuroendocrine 
traits.
 Is Aromatization Of T to E2 Needed For Masculinization Of The SDN?: The fetal 
oSDN is characterized by an abundant expression of aromatase and ERα suggesting that like 
in rodents, sheep brain masculinization and defeminization may require conversion of T to 
estradiol. However, daily treatment of mothers with the aromatase inhibitor 
androstatrienedione (ATD) had no effects on the sexual preferences and oSDN volumes of 
adult offspring (72,73). Nor did ATD-exposed rams show LH surge responses or behavioral 
receptivity in response to estradiol injections. The only difference was that ATD-exposed 
rams showed lower mounting activity than controls when they reached 18 months of age. 
Thus, it appears that estrogens are not essential for masculinization and defeminization of 
sheep brain. These results raise the question of whether masculinization of mate preferences 
and oSDN volume are controlled entirely through an androgen receptor mechanism or 
through the combined effects of both androgens and estrogens.
 Is Androgen Activity Responsible for Differentiation of Male oSDN?: Androgen 
receptors are also expressed in the developing fetal oSDN (74). Experiments were performed 
to test the involvement of androgen receptors in the sexual differentiation of sheep brain 
(75). If androgen receptors mediate masculinization, fetal exposure to the antiandrogen 
flutamide should reduce the size of the oSDN in males, but not in females. On the other 
hand, exposure to the androgen agonist DHT should increase the size of the oSDN in 
females, but not in males. Maternal flutamide treatment from GD 60 to 90 significantly 
reduced mean oSDN volumes in GD135 male fetuses. Paradoxically, maternal DHT 
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treatment during the same period also significantly reduced the oSDN volume of males. 
Neither treatment affected females. In a second experiment, fetuses were delivered during 
the final maternal treatments (GD85) to analyze whether these treatments elicited 
compensatory hormonal responses from the hypothalamic-pituitary-gonadal axis. Exposure 
to flutamide blocked negative feedback in males resulting in elevated serum levels of LH 
and T, but had no effect in females. Thus, flutamide exerts sufficient androgen receptor 
antagonism to reduce oSDN volume even when T is elevated. Exposure to DHT significantly 
suppressed LH concentrations in males and females and reduced T concentrations in males. 
These results demonstrate that DHT exerts negative feedback on the pituitary and 
consequently inhibits T secretion, which can explain why the oSDN volume was reduced in 
males and unaffected in females. Apparently the levels of DHT achieved in the fetal 
circulation were insufficient to support masculinization of the oSDN. These results provide 
convincing evidence that the prenatal program that masculinizes the oSDN in eugonadal 
male fetuses acts through the androgen receptor. However, it is also apparent that 
hypothalamic and pituitary are tonically suppressed in males during the gestational critical 
period for oSDN masculinization and respond to disruptions in androgen action with an 
opposing hormone response intended to stabilize the endocrine milieu (Figure 1). It is not 
yet known whether flutamide exposure exerts sufficient androgen receptor antagonism to 
alter male-typical sexual partner preference despite the compensatory increase in circulating 
T.
 Fetal Reprogramming by T of Reproductive and Metabolic Parameters in 
Male Sheep—Inappropriate exposure to androgens during gestation can alter the trajectory 
of lamb development and alter adult physiology. For example, excess of androgen exposure 
during gestation induces PCOS-like and metabolic traits in the female offspring in 
mammals, suggesting that the intrauterine environment may play a role in the etiology of 
PCOS (76–78). Studies from several laboratories demonstrate that pregnant sheep injected 
with T during part of their gestation give birth to female offspring, which have several 
reproductive and metabolic features resembling those observed in PCOS women. In the 
sheep model, T-treated pregnant ewes exhibit high plasma levels of T resembling those of 
adult males and plasma concentrations of insulin are similar to control pregnant sheep. The 
hyperandrogenic sheep model differs from human PCOS mothers, which are both 
hyperandrogenic and hyperinsulinemic. Thus, the sheep model isolates the effect of 
androgens from other stimuli such as insulin, and provides tissue samples for studies in the 
offspring.
In addition to the results obtained in the female offspring, recent studies have demonstrated 
that male sheep born to T-exposed mothers, exhibit an altered reproductive and metabolic 
phenotype. Biometric analysis of testis of adult males showed that Sertoli cell number was 
higher in males born to hyperandrogenic mothers (T-males) than in control males (C-males) 
whereas spermatogonia, spermatocytes and spermatids were lower (79,80). Higher numbers 
of Sertoli cells in the seminiferous tubules was found to be a common feature in testis from 
T-males from infancy through puberty (81) but not during fetal life (Recabarren et al., 
unpublished results). Paradoxically, the number of sperm cells was lower in the ejaculate of 
postpubertal and adult T-males (82). It is widely accepted that there is a strong correlation 
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between number of Sertoli cells and the sperm production in animals and humans (83,84). 
Consequently, a functional discrepancy exists in these T-males because there is no 
correlation between the number of sperm cells and the number of Sertoli cells. The ontogeny 
of this discrepancy is unknown. It may be initiated during fetal life and completed before or 
after puberty (81,85). In this regard, the mRNA expression of the Sertoli cell marker 
antimullerian hormone (AMH) was higher in fetal and in peripubertal T-males testis (86,87).
The hypothalamic-pituitary-gonadal axis is also altered in T-males. This is apparent in the 
characteristics of the LH pulsatility, and the response of the pituitary gland and testis to a 
GnRH stimulus. Features of LH pulsatility such as LH pulse amplitude and LH pulse nadir 
were higher in T-males than in C-males, suggesting a reprogramming of GnRH secretion or 
a higher pituitary responsiveness to GnRH since the LH pulse frequency was not modified 
(88). The latter explanation was supported by another study that found pituitary gland 
responsiveness to a GnRH challenge was higher in T-males of 30 weeks of age than in T-
males of 20 weeks of age. However, the release of T stimulated by the endogenous LH in T-
males of both ages was similar to that of C-males, suggesting that the responsiveness of the 
Leydig cell to the endogenous LH release was lower in T-males than in C-males (85). This 
may be due to modifications in the bioactivity of the LH released by the GnRH challenge 
because the T response to human chorionic gonadotropin (HCG) in adult T-males was 
similar to that of C-males (82). This reasoning was supported by the finding that mRNA 
expression of steroidogenic testicular enzymes in T-males was comparable to that of C-
males (81), suggesting that the testicular steroidogenesis was not altered. However, it is also 
possible that lower T secretion could be related to a low number of LH receptors, because 
the expression of LH receptors mRNA was lower in T-males than in C-males (81,89). In 
summary, the exposure to T during fetal development may be followed by: hypothalamic 
dysregulation of GnRH secretion, disturbances in the processing of LH secretion after a 
GnRH stimulus and probable modification in the isoforms of LH released. On the other 
hand, T secretion after LH stimulation may be also affected due to LH receptor availability. 
As a whole, fertility of these males may be impaired.
The intravenous glucose tolerance test (IVGTT) has been employed to evaluate various 
indices of insulin sensitivity in T- and C-males including, basal glucose/insulin ratio, the 
area under the insulin curve or mean insulin secretion, and the Insulin Sensitivity Index-
Composite (ISI-C) (90). Studies in human PCOS mothers find that their sons have an altered 
metabolic profile from infancy to adulthood, and they develop insulin resistance independent 
of body mass index (82). In the sheep model, the ISI-C and all other indices were similar 
between T-males and C-males during infancy, the prepubertal and postpubertal periods. It 
could be inferred from these results that an excess of T during fetal development has no 
impact on the insulin sensitivity during postnatal development. To further analyze the fetal 
reprogramming of the insulin-glucose homeostasis in males and the contribution of T, the 
insulin sensitivity was assessed in orchidectomized postpubertal C-males and T-males before 
and 48-h after an acute T challenge. Basal levels of insulin and glucagon were not different 
between groups before and after the T challenge. However, T-males released higher insulin 
compared to C-males during the first 20-min of the test after the T challenge. Plasma levels 
of glucose were not different between groups during the IVGTT, suggesting that a T 
challenge was more effective in the release of insulin in T-males under the glucose 
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stimulation. However, the ISI-C was lower in T-males after the T administration, suggesting 
a decrease in the insulin sensitivity in peripheral tissues. These findings are in contrast to 
those found in studies in human males born to PCOS mothers, where males exhibited 
metabolic disarrangements from infancy to adulthood including the lipid profile and the 
insulin sensitivity, while there was no alteration in the sperm cell concentrations or the 
GnRH responsiveness (91,92). However, plasma AMH concentrations were higher in 
children born to PCOS mothers than those born to control mothers suggesting that the 
Sertoli cell numbers were increased in the male offspring of PCOS-mothers, indicating a 
similar reproductive phenotype may exist in hyperandrogenic male offspring of humans and 
sheep (91). Further research is needed to explore this possibility.
In conclusion, the sheep model has advantages and disadvantages for studying the 
programming effect of T during fetal life on reproductive and metabolic parameters in 
offspring. Despite its limitations (93) it could help elucidate the sequelae associated with 
inappropriate androgen exposure during fetal development and uncover the cause of the 
neuroendocrine disturbances observed in the affected offspring. It is now apparent that both 
females and males are susceptible to the reprogramming effects of a hyperandrogenic 
intrauterine environment.
 II-Protective Effects of Steroid Hormones
 Progesterone
 Protective Effects of Progesterone in the Degenerative Spinal Cord—Under 
physiological conditions, progesterone is traditionally associated with female reproductive 
functions and pregnancy. Additionally, this steroid exerts neuroprotective and pro-
myelinating effects in the central and peripheral nervous system in acute and chronic 
diseases such as traumatic brain injury, stroke, ischemia, peripheral neuropathy of traumatic 
or diabetic origin, Alzheimer’s dementia and amyotrophic lateral sclerosis (ALS)(94–99). At 
the cellular and molecular level, progesterone modulates neuronal survival and plasticity, 
increases adult neurogenesis, favors the myelination process, inhibits lipid peroxidation, 
exerts anti-inflammatory properties and regulates astroglial plasticity (99,100). The central 
nervous system (CNS) expresses several specific progesterone receptors such as: 1) the 
classical intracellular progesterone receptor (PR), 2) several isoforms of the membrane PR 
(mPRα, β and γ), 3) the progesterone receptor membrane component type 1 (abbreviated 
PGRMC1 and formerly known as 25DX), and 4) sigma 1 receptors (99,101,102). Once 
progesterone reaches the nervous system, either from systemic circulation or produced 
locally in the brain, it can be metabolized into 5 alpha dihydroprogesterone (DHP), which is 
further converted into 3 alpha, 5 alpha tetrahydroprogesterone or allopregnanolone (103). 
Thus, the metabolism of progesterone inside the nervous system has a profound impact on 
its mechanism of action: while progesterone and DHP interact with the classical intracellular 
PR, allopregnanolone is a potent allosteric modulator of GABAa receptors.
The Wobbler mouse is an animal model of ALS, the most common motoneuron disease. 
Wobblers develop a chronic, progressive motoneuron degeneration with selective 
involvement of brain stem and cervical motoneurons (104). In contrast to ALS patients who 
show a sex difference in disease incidence, with higher frequency in men than in women 
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(105), the onset or the progression of the Wobbler disease did not correlate with sex (106). 
Histologically, ventral horn motoneurons of the cervical spinal cord experience a dramatic 
cytoplasmic vacuolar degeneration (107), associated with astrocytosis (108–110) and 
microglial activation (111). Oxidative stress events participate in this mechanism, a finding 
supported by abnormalities of mitochondrial function in Wobbler mice. In this regard, 
mitochondria contribute to the production of certain free radicals; namely, superoxide anion 
and nitric oxide (NO); the latter caused by the elevated activity of a mitochondrial nitric 
oxide synthase (mtNOS) (112). Excess levels of NO in association with increased generation 
of superoxide anions produce the formation of peroxynitrite (ONOO-) leading to oxidative 
damage. This situation leads to mitochondrial swelling and inhibition of the electron 
transport chain (113). At the ultrastructural level, vacuolated motoneurons from Wobbler 
mice present cristolysis and disruption of outer and inner mitochondrial membranes (114).
Progesterone administration to Wobblers exerts neuroprotective and anti-inflammatory 
effects such as: 1) lower number of damaged/vacuolated motoneurons, 2) increased 
expression of brain derived neurotrophic factor in motoneurons and oligodendrocytes, 3) 
restoration of cholinergic neurotransmission and of axonal transport and 4) inhibitory effects 
on astrocytosis (94,114). Recent work suggests that the motoneuron protective effects of 
progesterone may also depend on the regulation of mitochondrial function.
 Progesterone Prevents Mitochondrial Dysfunction In The Degenerative Spinal Cord 
Of Wobbler Mice: Mitochondria from early stage Wobblers show higher content of nNOS 
(mtNOS) in the cervical, but not lumbar spinal cord compared to controls. On the contrary, 
this region presents unchanged levels of cytosolic nNOS in the same groups. These events 
are associated with increased staining of NADPH-diaphorase/NOS in Wobbler’s 
motoneurons. The changes in intramitochondrial nNOS in Wobblers have deleterious 
consequences for the activity of the electron transport chain. In this regard, cervical cord of 
Wobblers shows compromised activities of complexes I and II–III in contrast to normal 
activities of cytochrome oxidase. Progesterone treatment decreases the level of 
mitochondrial nNOS in the cervical region and prevents the fall in the activity of complex I 
(106). These progesterone effects are associated with a reduction of the percentage of 
vacuolated/damaged motoneurons in Wobbler’s cervical region, indicating that 
mitochondrial abnormalities are linked to motoneuron degeneration (Figure 2). Additionally, 
decreased activity and immunostaining of the intramitochondrial enzyme manganese 
superoxide dismutase (MnSOD) as well as an accumulation of the amyloid precursor protein 
(APP) are also present in Wobblers motoneurons. The increase of APP at the level of the 
soma suggests impaired anterograde transport of APP to the terminal. Likewise, transport 
impairment may facilitate accumulation of nNOS in the cell body and enhanced access of 
this enzyme to the mitochondria. Exogenous administration of progesterone prevents these 
abnormalities (106). Hence, administration of progesterone to clinically afflicted Wobblers 
(1) blocks the abnormal increase of mitochondrial nNOS and normalizes respiratory 
complex I; (2) decreases APP accumulation, a signal of axonal degeneration, and (3) 
enhances superoxide dismutation. Therefore, progesterone neuroprotection reduces 
mitochondriopathy of the cervical spinal cord of Wobbler mice. The enhancement of 
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MnSOD activity and immunostaining by progesterone in the Wobbler supports the concept 
that this steroid may act as an antioxidant molecule arresting neurodegeneration.
 Steroid Hormones and Human ALS: ALS is an adult progressive neurodegenerative 
disorder affecting the upper and lower motor neurons (115). Respiratory failure is the most 
frequent cause of death in these patients (116). Worse prognostic factors in ALS are: a) 
bulbar onset, b) advanced age, and c) short time between onset and diagnosis (117). 
Epidemiological studies show higher frequency of ALS in men than women until 
menopause when it becomes the same for both sexes. Thus, the suggestion has been made 
that sex steroid hormones may play a role in the disease susceptibility (105,118). Recently, 
ALS has been considered a hormonal disorder involving changes of circulating gonadal 
steroids (118). This neurodegenerative disease also represents a stressful condition, in which 
changes in the hypothalamic-pituitary-adrenal (HPA) axis have been reported sporadically in 
ALS patients. Thus, loss of circadian rhythm of cortisol in ALS was first reported by 
Patacchioli et al (119), whereas Monachelli et al. has recently found serum cortisol levels 
increases in ALS patients, further suggesting HPA axis dysfunction (120,121).
Circulating levels of progesterone are increased in male ALS patients in comparison to male 
control subjects. Such levels correlate positively with survival time and factors predicting 
better prognosis. In this regard, endogenous progesterone levels are elevated in benign forms 
of the disease such as in patients younger than 55 years of age and presenting spinal onset. 
In the elderly, peripheral circulation of progesterone may depend on adrenal steroid 
production (122). Moreover, changes of androgens and estrogens also occur in ALS and 
their animal models (123). In some men with ALS, free T levels are in the low to normal 
range, whereas the finding of a low index-to-ring finger length ratio (2D:4D ratio) suggests 
that greater prenatal T exposure may play a role in motor neuronal vulnerability in 
adulthood (124). In contrast, women ALS patients show higher circulating levels of T than 
healthy female subjects. In this group of patients, circulating levels of T do not decline with 
increasing age as it does in controls. The concentration of sex steroids in ALS patients also 
bears a differential relationship with respiratory status and disease progression. Thus, 
respiratory symptoms and a decline in forced vital capacity (FVC %) are associated with a 
shorter survival in ALS patients. ALS patients with higher T levels and lower progesterone/
free T ratio exhibit a greater loss of respiratory function or a more rapid decline of FVC% 
(122). These results suggest that certain steroids may play a “protective” role while others 
have a negative influence on parameters vital for the progression and final outcome of the 
disease. In the transgenic superoxide dismutase-1 (SOD1) and Wobbler mouse models of 
ALS, it has been shown that ovariectomy leads to a significant acceleration of the disease, 
whereas estradiol or progesterone treatment significantly delays disease progression (125).
Given that progesterone’s biological effects are essentially mediated by binding to the 
classical intracellular PR, Gargiulo-Monachelli et al (126) demonstrated the presence of PR 
immunoreactivity in the cytoplasm of motor neurons and, more prominently, in axonal 
processes and large arteries. Indeed, the authors reported that PR staining was stronger in 
nerve roots and large arteries from ALS compared to control spinal cords (126). 
Immunocytochemistry studies carried out in the rat spinal cord demonstrated that neurons 
and glial cells localized in the ventral horn are PR positive not only in the cytoplasm but also 
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in the nucleus (127). Evidence of cytoplasmic PR in the human spinal cord may suggest the 
intriguing possibility that progesterone could be acting through extranuclear mechanisms of 
hormone action. The presence of extranuclear PR has also been reported in the pre- and 
post-synaptic structures in the rat hippocampus that, may be linked to the control of neuronal 
excitability and synaptic plasticity (128). The colocalization of PR with markers of 
phosphorylated high molecular weight neurofilaments such as SMI-31 suggests that the PR 
may have an as yet unknown role in these cells. As mentioned above, progesterone displays 
a neuroprotective role in different pathologies of the nervous system (126). In addition, 
progesterone and DHP reduce axonal supernumerary sprouts and promote nerve repair by 
influencing the expression of the peripheral myelin proteins P0 and PMP22. The finding that 
progesterone and DHP are able to interact with the PR further suggests a role for this 
classical steroid receptor in nerve repair (103). Until the role of PR in ALS is clarified, it 
should be mentioned that expression of this receptor in ALS affected spinal cord is not 
identical to that seen in controls. These findings suggest a role for the PR and progesterone 
in this disease, probably in relation to regeneration and neuroprotection, as reported for 
animal models. Consequently, future studies are needed to clearly establish progesterone 
neuroprotection in ALS, as may be inferred from previous studies in other 
neurodegenerative and injury models.
 III-Estrogen-induced Tumorigenesis
 Prolactinomas and Notch-signaling
 Pituitary Cell line derived from estrogen treated rats: a model for resistant 
prolactinomas—Prolactinomas are the most frequent tumors in adults accounting for 60% 
of all functioning pituitary tumors. They are usually treated with dopaminergic agents and 
are frequently benign. In addition, 15% may be resistant to classical pharmacological 
therapy, become invasive and aggressive, and require extirpation. In these cases, the decrease 
of dopamine D2 receptor (D2R) expression is considered hallmark for loss of dopamine 
responsiveness and indicate that alternative therapies are needed to treat these tumors.
The estrogen-treated rat is an interesting and well-studied model of pituitary hyperplasia. 
Increased pituitary weight, hyperprolactinemia, lactotrope hyperplasia, and reduced 
dopaminergic action at the pituitary level are physiological consequences in chronically 
estrogenized female rats (129,130). The GH3 cell line, one of the best models developed to 
study prolactinomas in vitro was generated by treating a rat with high doses of estrogens, in 
which a prolactinoma developed (131). By extracting this tumor, the GH3 cell line was 
generated through cellular culture methods. Interestingly, this cell line lacks D2R, which is 
the principal feature of clinical dopamine agonist resistant prolactinoma. This feature makes 
the GH3 cell line a good experimental model to study prolactinomas and describe the 
molecular characteristics in vitro, or even in vivo, in a more physiological context. It is well 
known that GH3 cells secrete large amounts of prolactin (Prl) and growth hormone (GH), 
when they are maintained in cell culture or even when used for in vivo experiments (131–
137).
In humans, Prl-secreting pituitary adenomas arise most commonly from the lateral wings of 
the anterior pituitary and fill the sella turcica as they progress leading to compression of the 
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normal anterior and posterior lobes (130,138,139). Tumors range in size from small 
microadenomas to large invasive tumors with extra-sellar extension. Microadenomas, tumors 
with less than 1cm in diameter at diagnosis, are observed in high proportions in patients.
(140,141).
The physiological symptoms of prolactinomas are galactorrhea and amenorrhea in women, 
and decreased libido or impotence in men (142). Gonadal dysfunction generally associated 
with amenorrhea, oligomenorrhea with anovulation, or infertility is present in approximately 
90% of women with prolactinomas (143,144). Gonadal dysfunction in these women is due 
to interference with the hypothalamic-pituitary-gonadal axis by the hyperprolactinemia and, 
except in patients with large or invasive adenomas, is not due to destruction of the 
gonadotropin secreting cells. On the other hand, in men, the usual manifestations for clinical 
consultation are those of hypogonadism. The initial symptom is decreased libido, which may 
be initially regarded by both the patient and physician as a psychological factor; thus the 
recognition of prolactinomas in men is frequently delayed and marked hyperprolactinemia 
occurs. (145–148)
In the last 10 years a subset population of cells of the pituitary gland called the Side 
Population (SP) has been identified. This small subset of SP cells, have several 
characteristics reminiscent of stem/progenitor cells and of early-embryonic pituitary cells 
(149–151).
Pituitary adenomas were found to contain self-renewing sphere-forming cells, considered a 
property of Cancer Stem Cells (CSC). Whole-genome expression profiling performed in SP 
cells, which contain CSC, compared to the tumor bulk cells from somatotropinomas and 
non-functioning adenomas revealed an upregulation of several Notch system (receptors and 
ligands) components in humans (152). The Notch system has a broad expression both in 
human (153,154) (Zubeldia Brenner L. unpublished results) and mice pituitary (149–151), 
as well as in rat pituitary (Zubeldia Brenner L. unpublished results).
The cellular and molecular mechanisms that initiate the formation of prolactinomas are 
largely unknown. In this regard, the participation of Notch receptors in prolactinoma 
development has not been studied in detail. The Notch receptors are involved in a wide 
group of processes during development of eukaryotic cells such as proliferation, migration, 
differentiation and apoptosis (155–158). Thus, the Notch system seems to function as a 
general developmental tool that is used to direct cell fate and, consequently, to shape a living 
organism (155,156).
Mammals possess four different Notch receptors, referred to as Notch-1, Notch-2, Notch-3, 
and Notch-4. The Notch receptor is a single-pass transmembrane receptor protein. It is a 
hetero-oligomer composed of a large extracellular portion, which associates in a calcium-
dependent, non-covalent interaction with a smaller piece of the Notch protein composed of a 
short extracellular region, a single transmembrane-pass, and a small intracellular region. The 
receptor is normally triggered via direct cell-to-cell contact, in which the transmembrane 
proteins of the cells in direct contact form the ligands that, interacts with the extracellular 
domain of the Notch receptor on an adjacent cell (159). Upon ligand binding, the receptor 
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suffers two proteolytic events due to the activation mechanism (160,161). Notch receptors 
are cleaved near the exterior side of the plasma membrane, and then a posterior cleavage in 
the transmembrane domain mediated by a gamma-secretase enzyme complex liberates the 
intracellular domain of the receptor (Notch intracellular domain, NICD) to the cytoplasm. 
NICD acts as a transcription factor, translocating to the nucleus after the cleavage to form a 
multiprotein complex with the ubiquitously expressed CSL transcription factor. In the 
absence of NICD, CSL is complexed with co-repressors. When NICD binds CSL, specific 
co-activators are recruited resulting in a transcriptional activation of the target genes (162). 
The transcriptional targets of the Notch system include differentiation related factors, cell 
cycle regulators (p21 and cyclin D1) and regulators of apoptosis. Transcription factors of the 
Hairy/enhancer of split (Hes) and Hes related (HRT/HRP/Hey) families (163) are also part 
of the principal targets. These proteins belong to the basic helix-loop-helix family of 
transcription factors and bind specific sequences in the promoter region of target genes and 
repress the transcription through recruitment of a set of co-repressors.
Notch receptors are involved in several physiological processes. Furthermore, there are 
several pathologies in which Notch receptors are seriously dysregulated. In cancer and 
abnormal neoplasic proliferation, Notch receptors are altered, and may be upregulated or 
downregulated depending on the tissue and context involved (164–166). Within the four 
receptors Notch-1 and Notch-3 are the most frequently mentioned in tumor development and 
cancer (153,154,159).
Tumorigenesis and neural development are part of the processes in which Notch-3 has been 
described. Furthermore, the Notch-3 receptor and its ligands are implicated in cellular 
differentiation and in some cases promote pituitary cell growth and tumor formation in non- 
functioning adenomas (153,154).
Notch-3 is also expressed in the SP cells of the adult anterior pituitary gland. In humans, 
Notch-3 expression in non-functioning pituitary tumors is markedly higher than in normal 
pituitary tissue (153,154). Strikingly the Dlk-1 gene deletion, one of the Notch ligands, 
results in a developmental defect in somatolactotrophs (159).
Notch-1 was also detected in the anterior pituitary of adult mice (151). Recently Zubeldia-
Brenner L et al. (unpublished results), detected the additional mammalian Notch receptors 
(Notch-2, 3, and 4) and other key downstream target genes (Hes-1, Hes-5 as well as Hey-1 
and Hey-2) using RT-PCR (Zubeldia-Brenner L et al. unpublished results).
In recent experiments, xenotropic tumors were generated by injecting GH3 cells into Nude/
Nude mice to test the role of Notch signaling in tumor growth and progression. Once the 
tumors developed, mice were treated with DAPT, a drug that blocks the Notch pathway by 
inhibiting the gamma-secretase. Tumor volumes were significantly smaller in mice treated 
with DAPT compared with the controls (Zubeldia-Brenner unpublished data). These results 
suggest that Notch receptors play a critical role in the hormonal function of these pituitary 
tumors, as well as in the normal physiological context of the pituitary enhancing or 
downregulating the secretion of Prl and GH.
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 Summary and Conclusion
This review highlights the important effects of steroid and peptidergic hormones at central 
and peripheral levels of the neuroendocrine axis and illustrates a wide variety of neural 
processes in which they participate. The impact of steroids on neuroendocrine processes is 
very broad, and in this review we included their impact on PCO, brain sexual differentiation, 
ALS, and the etiology of prolactinomas.
Evidence has been presented to show that inappropriate prenatal exposure to environmental 
estrogen can alter normal development of the ovary leading to adult ovarian pathologies. 
This can be transmitted to the next generation through epigenetic mechanisms that 
reprogram genes. Moreover, the prenatal hormone milieu also plays an important role in 
brain sexual differentiation revealing that sexual preferences are also under the control of 
steroid hormones.
Further examples in which steroid hormones are involved are the protective effect of 
progesterone in the degenerative spinal cord and ALS, and the role of estrogen and Notch 
signaling in prolactin secreting pituitary tumors.
In conclusion, the developmental studies presented here implicate fetal exposure to 
hormonal and environmental compounds as an important variable that may developmentally 
reprogram the neural mechanisms regulating adult reproductive function. They reveal 
important fetal antecedents of adult gonadal dysfunctions that impact fertility and provide 
new insights into the prenatal hormone influences on adult sexuality. Moreover, the 
functional studies of neurodegeneration and tumorigenesis have identified novel cellular and 
molecular control points regulated by steroid hormones that may constitute future 
therapeutic targets. The global processes influenced by steroid hormones are tightly 
regulated and so precise that the presence of hormonal disruptors or imbalances in the 
neuroendocrine milieu may generate altered phenotypes or predispose individuals to serious 
pathologies. The insights gained from this research further our understanding of the 
elaborate and intricate regulation that steroid hormones exert on the central and peripheral 
nervous systems throughout life.
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Figure 1. 
Response of male fetal hypothalamic-pituitary-testis axis to vehicle (Control), androgen 
antagonist flutamide and androgen agonist dihydrotestosterone (DHT). Pregnant ewes 
received injections of vehicle, flutamide and DHT from gestation day (GD) 60 to 84 and 
fetuses were delivered on GD85 for evaluation. In control eugonadal male fetuses, LH 
secretion is tonically suppressed by androgens at this age to regulate normal testosterone (T) 
secretion driving normal androgen action which, in turn, masculinizes the ovine sexually 
dimorphic nucleus (oSDN). Exposure to flutamide blocks negative feedback resulting in 
elevated LH concentrations, enlarged testis & increased testicular T secretion. The increased 
T competes with the competitive antagonist flutamide for the androgen receptor and leads to 
partial, instead of full, inhibition of oSDN masculinization. Exogenous DHT exposure 
enhances negative feedback further suppressing LH secretion leading to smaller testis and 
reduced levels of testicular T. The result of DHT treatment is reduced exposure of the 
developing SDN to endogenous T and incomplete masculinization. Both results are 
consistent with a role for androgen receptor activation in the masculinization of the ovine 
SDN.
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Figure 2. 
A: Digital images of paraffin sections of the ventral horn from cervical spinal cord stained 
with cresyl violet. Images show motoneurons with normal appearance (upper left), two 
intensely vacuolated cells (arrows) in an untreated Wobbler mouse (middle graph), and 4 
motoneurons with normal appearance and 1 vacuolated motoneuron (arrow) in a 
progesterone treated Wobbler (upper right) Magnification: 600X. Lower graphs show 
electron microscopy of mitochondria from a motoneuron of a control mouse (lower left), an 
untreated Wobbler mouse (middle) and a Wobbler mouse receiving progesterone (PROG) 
(lower right). Motoneurons from Wobblers show massive vacuolation disrupting the outer, 
inner mitochondrial membranes and cristae (lower middle graph, asterisk). Motoneurons 
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from PROG treated Wobblers show some mitochondria with a better conservation of the 
membrane system, including the cristae. Magnification: 50,000X. B: Activity of the 
mitochondrial respiratory enzyme complex I in the cervical region of the spinal cord of 
Wobbler mice and Wobbler mice receiving progesterone treatment. Progesterone increased 
complex I activity in cervical spinal cord from Wobblers (*** p<0.001 vs. Wobbler). Results 
were expressed as % of complex I activity of control. C: Content of nNOS and MnSOD in 
mitochondrial fractions from the cervical cord of Wobbler mice and Wobbler receiving 
PROG. Wobbler vacuolated mitochondria showed high expression of mitochondrial nNOS 
(nNOSmt) and low activity and expression of manganese superoxide dismutase (MnSOD). 
Progesterone treatment in Wobblers significantly modified the high nNOSmt and the low 
MnSOD contents in mitochondria.
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